PharmaShots | Incisive News in 3 Shots

Subscribe Now

Endometrial Carcinoma

Merck and Eisai Receive the US FDA‘s Priority Review for Keytruda (pembrolizumab) + Lenvima (lenvatinib) to Treat Advanced Renal Cell Carcinoma and Endometrial Carcinoma

Merck and Eisai Receive the US FDA‘s Priority Review for Keytruda (pembrolizumab) + Lenvima (lenvatinib) to Treat Advanced Renal C...

May 7, 2021

Merck's Keytruda (pembrolizumab) + Eisai's Lenvima (lenvatinib) Receives FDA's Approval for Certain Types of Endometrial Carcinoma

Merck's Keytruda (pembrolizumab) + Eisai's Lenvima (lenvatinib) Receives FDA's Approval for Certain Types of Endometrial Carcinoma

September 18, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us